Infectious Diseases, Biosynthetic Chemistry, Wyeth Research, Pearl River, NY 10965, USA.
Diagn Microbiol Infect Dis. 2010 Apr;66(4):407-18. doi: 10.1016/j.diagmicrobio.2009.11.009.
The in vitro activity of tigecycline and comparative antimicrobial agents was evaluated against 1828 primary baseline pathogens isolated from 844 patients enrolled in the phase 3 clinical trials investigating the efficacy of tigecycline in diabetic foot infection (DFI). The trials were global, enrolling patients in 30 countries. Tigecycline was active against the most prevalent pathogens in DFI, including Gram-positive and Gram-negative isolates of both aerobic and anaerobic bacteria with 95% of MICs < or =2 microg/mL for the entire collection. The spectrum of activity of tigecycline included important pathogens for DFI, such as Staphylococcus aureus, Enterococcus faecalis, Streptococcus agalactiae, Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Bacteroides fragilis. As reported previously, Pseudomonas aeruginosa and several pathogens in the Proteeae group were generally less susceptible to tigecycline by comparison to other Gram-negative pathogens. The excellent in vitro expanded broad-spectrum activity of tigecycline in the clinical isolates confirmed the potential utility of tigecycline for pathogens associated with DFIs.
替加环素和比较抗菌药物的体外活性评估了 1828 个从 844 名糖尿病足感染（DFI）三期临床试验入组患者中分离的主要基线病原体。这些试验是全球性的，在 30 个国家招募了患者。替加环素对 DFI 中最常见的病原体具有活性，包括需氧和厌氧革兰阳性和革兰阴性菌的分离株，整个收集物中 95%的 MICs<或=2μg/ml。替加环素的活性谱包括 DFI 的重要病原体，如金黄色葡萄球菌、粪肠球菌、无乳链球菌、大肠杆菌、阴沟肠杆菌、肺炎克雷伯菌和脆弱拟杆菌。如前所述，与其他革兰氏阴性病原体相比，铜绿假单胞菌和 Proteeae 组的几种病原体通常对替加环素的敏感性较低。替加环素在临床分离株中具有出色的体外广谱活性，证实了替加环素对与 DFI 相关病原体的潜在应用价值。
